Prognostic Parameters of Palbociclib in HR+/HER2-Advanced Breast Cancer: A Narrative Review

被引：1
|
作者：
Wang, Wei [1 ,2 ]
Wu, Jiayi [1 ,3 ]
Chen, Keyu [1 ,3 ]
Wang, Xiaojia [1 ]
Shao, Xiying [1 ]
机构：
[1] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Med Oncol,Breast Canc, 1 Banshandong Rd, Hangzhou, Peoples R China
[2] Wenzhou Med Univ, Dept Clin Med, Wenzhou, Peoples R China
[3] Zhejiang Chinese Med Univ, Dept Clin Med, Hangzhou, Peoples R China
来源：
TECHNOLOGY IN CANCER RESEARCH & TREATMENT | 2023年 / 22卷
关键词：
breast cancer; palbociclib; CDK4; 6; inhibitor; prognostic parameters; LETROZOLE;
D O I：
10.1177/15330338231173504
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Recent studies have demonstrated that the combination of Cyclin-Dependent Kinase 4/6 Inhibitor (CDK4/6i) and endocrine therapy (ET) is more effective than ET alone and significantly improves progression-free survival (PFS) and overall survival (OS) in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor-2 negative (HER2-) breast cancer (BC). Palbociclib is the first CDK4/6i approved for use, and its clinical advantages have been shown. However, 30% of patients will continue to develop secondary drug resistance. Therefore, exploring the parameters that can predict the efficacy of Palbociclib and developing a clinical prediction model is essential for evaluating the prognosis of patients.
引用
收藏
页数：9
相关论文
共 50 条
  • [1] Prognostic Parameters of Palbociclib in HR+/HER2-Advanced Breast Cancer: A Narrative Review
    Wang, Wei
    Wu, Jiayi
    Chen, Keyu
    Wang, Xiaojia
    Shao, Xiying
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2023, 22
  • [2] Patterns and outcomes in HR+/HER2-advanced/metastatic breast cancer patients in Brazil receiving palbociclib
    Simon, Patricia
    Jain, Ankita
    Guarin, Alexandra
    Piton, Luciana
    Carvalho, Carla Fabrine
    Lima, Julia
    Nazareth, Felipe
    FUTURE ONCOLOGY, 2024, : 2647 - 2659
  • [3] Ribociclib in HR+/HER2-Advanced or Metastatic Breast Cancer Patients
    Rascon, Kaitlin
    Flajc, Goran
    De Angelis, Carmine
    Liu, Xinli
    Trivedi, Meghana V.
    Ekinci, Ekim
    ANNALS OF PHARMACOTHERAPY, 2019, 53 (05) : 501 - 509
  • [4] Matching-adjusted indirect treatment comparison of ribociclib and palbociclib in HR+, HER2-advanced breast cancer
    Tremblay, Gabriel
    Chandiwana, David
    Dolph, Mike
    Hearnden, Jaclyn
    Forsythe, Anna
    Monaco, Mauricio
    CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 1319 - 1327
  • [5] Real-World Palbociclib Use in HR+/HER2-Advanced Breast Cancer in Canada: The IRIS Study
    Mycock, Katie
    Zhan, Lin
    Taylor-Stokes, Gavin
    Milligan, Gary
    Mitra, Debanjali
    CURRENT ONCOLOGY, 2021, 28 (01) : 678 - 688
  • [6] Outcomes of male patients with HR+/HER2-advanced breast cancer receiving palbociclib in the real-world POLARIS study
    Blum, Joanne L.
    Dicristo, Caroline
    Gordon, David
    Karuturi, Meghan S.
    Oubre, David
    Jepsen, Erin
    Cuevas, Juan
    Lakhanpal, Shailendra
    Montelongo, Monica Z.
    Zhang, Zhe
    Cappelleri, Joseph C.
    Wang, Yao
    Tripathy, Debu
    BREAST CANCER RESEARCH AND TREATMENT, 2024, 203 (03) : 463 - 475
  • [7] Palbociclib plus endocrine therapy in older women with HR+/HER2-advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies
    Rugo, Hope S.
    Turner, Nicholas C.
    Finn, Richard S.
    Joy, Anil A.
    Verma, Sunil
    Harbeck, Nadia
    Masuda, Norikazu
    Im, Seock-Ah
    Huang, Xin
    Kim, Sindy
    Sun, Wan
    Iyer, Shrividya
    Schnell, Patrick
    Bartlett, Cynthia Huang
    Johnston, Stephen
    EUROPEAN JOURNAL OF CANCER, 2018, 101 : 123 - 133
  • [8] Efficacy and Safety of Abemaciclib in Combination With Endocrine Therapy for HR+/HER2-Advanced or Metastatic Breast Cancer
    Qureshi, Zaheer
    Jamil, Abdur
    Fatima, Eeshal
    Altaf, Faryal
    Siddique, Rimsha
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2025, 48 (01): : 6 - 15
  • [9] Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2-advanced breast cancer
    Corona, Silvia Paola
    Generali, Daniele
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 : 321 - 330
  • [10] Demographic Characteristics and Treatment Patterns Among Patients Receiving Palbociclib for HR+/HER2-Advanced Breast Cancer: A Nationwide Real-World Experience
    Boer, Katalin
    Rubovszky, Gabor
    Rokszin, Gyorgy
    Abonyi-Toth, Zsolt
    Foldesi, Csenge
    Dank, Magdolna
    ONCOTARGETS AND THERAPY, 2021, 14 : 3971 - 3981
12345